Declining Risk of Sudden Cardiac Death in Heart Failure: Fact or Myth?

Area of Science:

• Cardiology
• Heart Failure Research
• Sudden Cardiac Death Studies

Background:

• Growing belief that sudden cardiac death (SCD) risk is decreasing in heart failure (HF) patients on guideline-directed medical therapy (GDMT).
• Editorials suggest arrhythmic SCD is no longer a significant threat for HF patients undergoing GDMT.

Purpose of the Study:

• To critically evaluate whether SCD risk has truly declined in HF trials and real-world settings.
• To assess if residual SCD risk warrants continued use of implantable cardioverter defibrillators (ICDs) despite GDMT.
• To examine the translation of HF trial findings to clinical practice.

Main Methods:

• Review of existing data from heart failure clinical trials.
• Analysis of real-world evidence regarding SCD incidence.
• Critical appraisal of studies on GDMT and device therapy in HF.

Main Results:

• Evidence suggests SCD has not decreased in HF trials or in real-world populations.
• Data from trials not adhering to guideline-directed device therapy (GDDТ) are insufficient to delay ICD implantation.
• Challenges exist in applying HF trial results to diverse real-world patient populations.

Conclusions:

• The perceived decline in SCD risk among HF patients may be inaccurate.
• ICD therapy remains crucial for managing residual SCD risk in chronic HF.
• Future HF trials should incorporate GDDТ to better define the role of ICDs.